Moreover, because critical steps leading to CAVD, such as dystrophic calcification and osteogenesis, mimic processes identified in atherosclerotic calcification (40, 41), the efficacy of a Ca2+ channel antagonist in the VIC cultures resonates with previous clinical trial data (e.g., PREVENT, CAMELOT, ACCOMPLISH) showing that CaV1.2 Ca2+ channel antagonists reduced cardiovascular events and caused regression of atherosclerotic plaques (42–44), which is especially notable because the CAMELOT trial researchers observed a benefit with amlodipine in patients with normal blood pressure. This evidence concerns the gene CACNA1C and congenital bilateral aplasia of vas deferens from CFTR mutation.